SDX alot confidence, 10c on horizon. imo and DD. next week....

SDX alot confidence, 10c on horizon. imo and DD. next week.
fundamentals is huge and alot cash on board. The giant is about to wake up. great revenue, soon huge profits. bluechip client's and partners.
with out revenue there is no company.
stocks we have witness , market cap 100million and still a R&D company. So SDX will be huge.


products: SIEN-NET™ / EXO-NET™ / hTERT test / thyroid cancer trials / novel IVD 

confidence:

- commerical deal, effective and scalable commercial process to bring therapeutic exosomes into routine use.

- Sienna has completed its third major regulatory milestone for the quarter, receiving Therapeutic Goods Administration (TGA) listing on the Australian Register of Therapeutic Goods (ARTG) for the sale of its Class 2 IVD in Australia.


- Dr Emily Stein and Dr Peter French joined the Sienna team from Sevident as part of the acquisition, and they are working hard on a range of new projects to create expanded revenue opportunities.

- VivaZome is developing a large-scale, advanced manufacturing process for exosome production and purification.

- deals in South America. The distribution agreement – Sienna’s first in South America – represents another significant milestone in Sienna’s geographical expansion strategy.

- Sienna continues expansion into Asia with the signing of a distribution partner for Singapore.

- The distribution agreement provides Mirax Corporation, Ltd. (Mirax) with the right to sell Sienna’s product to Korean pathology laboratories, where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cance

- massive deal America.The acquisition will assist Sienna to build a pipeline of novel diagnostic technologies that meet unmet clinical needs in the pathology market. The sample preparation technology, which we now call SIEN-NET, can isolate and capture molecular and cellular biomarkers from small clinical sample volumes, with high sensitivity and specificity. Successful development of SIEN-NET will enable Sienna to enter the liquid biopsy market, which is estimated to be worth $28.6 billion.

- Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered

- china. The distribution agreement for mainland China is a milestone in Sienna’s geographical expansion strategy. The agreement gives GaoYuan the exclusive right to sell Sienna’s in-vitro diagnostic hTERT test to pathology labs where it will be used as an adjunct to urine cytology, 


And final FDA approval. that was pointed out last year.